COLABORA El Meu Clínic . Este enlace se abre en una nueva pestaña.
Buscar
COLABORA El Meu Clínic . Este enlace se abre en una nueva pestaña.
Hilo de navegación

Ana Carrio

Publicaciones destacadas

  • NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease

    Autores:
    Martinez D; Navarro A; Martinez-Trillos A; Molina-Urra R; Gonzalez-Farre B;
    (...)
    Siebert R; Wotherspoon A; Beà S; Matutes E; Campo E .
    Referencia: AMERICAN JOURNAL OF SURGICAL PATHOLOGY.

  • LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.

    Autores:
    Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A;
    (...)
    Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E; Grup per l’Estudi dels Limfomes de Catalunya i Balears (GELCAB).
    Referencia: AMERICAN JOURNAL OF SURGICAL PATHOLOGY.

  • CHRONIC LYMPHOCYTIC LEUKEMIA: PROGNOSTIC VALUE OF CLINICAL STAGES AND CLASSICAL PROGNOSTIC PARAMETERS DEPENDING ON TREATMENT MODALITY

    Autores:
    Baumann, T.; Delgado, J.; Mozas, P.; Ortiz-Maldonado, V.; Santacruz, R.;
    (...)
    Aymerich, M.; Villamor, N.; Costa, D.; Carrio, A.; Montserrat, E.;.
    Referencia: HAEMATOLOGICA.

  • CLL: IS LYMPHOCYTE DOUBLING TIME (LDT) A RELEVANT PROGNOSTIC PARAMETER IN THE ERA OF PROGNOSTIC BIOMARKERS?

    Autores:
    Baumann, T.; Delgado, J.; Mozas, P.; Ortiz-Maldonado, V.; Santacruz, R.;
    (...)
    Aymerich, M.; Villamor, N.; Costa, D.; Carrio, A.; Montserrat, E.;.
    Referencia: HAEMATOLOGICA.

  • Patients' outcome according to clinical stage and prognostic significance of classical parameters before and after the introduction of purine analogs and chemoimmunotherapy in the treatment of chronic lymphocytic leukemia

    Autores:
    Baumann, Tycho; Delgado, Julio; Mozas, Pablo; Ortiz-Maldonado, Valentin; Santacruz, Rodrigo;
    (...)
    Aymerich, Marta; Villamor, Neus; Costa, Dolors; Carrio, Ana; Montserrat, Emili;.
    Referencia: LEUKEMIA AND LYMPHOMA.

  • CLL: a reassessment of the clinical significance of lymphocyte doubling time (LDT) in the era of prognostic biomarkers

    Autores:
    Baumann, Tycho; Delgado, Julio; Mozas, Pablo; Ortiz-Maldonado, Valentin; Santacruz, Rodrigo;
    (...)
    Aymerich, Marta; Villamor, Neus; Costa, Dolors; Carrio, Ana; Montserrat, Emili;.
    Referencia: LEUKEMIA AND LYMPHOMA.

  • Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.

    Autores:
    Karube K; Enjuanes A; Dlouhy I; Jares P; Martin-Garcia D;
    (...)
    Schmitz R; Staudt LM; Salaverria I; López-Guillermo A; Campo E..
    Referencia: Leukemia 2018.

  • CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status

    Autores:
    Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Rozman M;
    (...)
    López C; Costa D; Carrió A; Villamor N; Montserrat E .
    Referencia: BRITISH JOURNAL OF HAEMATOLOGY 2016.

  • Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia

    Autores:
    Salaverria, Itziar; Martin-Garcia, David; Lopez, Cristina; Clot, Guillem; Garcia-Aragones, Manel;
    (...)
    Campo, Elias; Dyer, Martin J S; Siebert, Reiner; Armengol, Lluis; Bea, Silvia.
    Referencia: Genes Chromosomes & Cancer 2015.